Murepavadin Antibiotic Well-tolerated by Animals Infected with Pseudomonas Aeruginosa, Preclinical D
Murepavadin (POL7080), Polyphor‘s lead investigational antibiotic targeting Gram-negative bacteria, behaved as expected and was...
#NACFC2018 – RPL554 Shows Promising Results in CF Studies
Positive data from preclinical and Phase 2a studies evaluating the investigational cystic fibrosis (CF) treatment RPL554 were presented...
Decibel Obtains Exclusive License for ORC-13661 for Prevention of Antibiotic-related Ototoxicity
Decibel Therapeutics received worldwide, exclusive rights to develop and commercialize ORC-13661, Oricula Therapeutics’ investigational...
Arcturus’ RNA Therapy for CF Shows Promise in Preclinical Studies, Company Announces
Arcturus Therapeutics’ RNA-based approach enables the production of healthy CFTR— the protein whose dysfunction is key in cystic fibrosis...
AIT’s Inhaled Nitric Oxide Shows Potential in Fighting Bacterial Infection Prevalent in CF Patients
Inhaled nitric oxide (NO) was shown to be an effective antibacterial agent against Mycobacterium abscessus infection in preclinical...